(S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate | 716339-53-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate
• 英文别名: t-butyl 4-[(3S)-4-benzyl-3-methylpiperazin-1-yl]-4-methylpiperidine-1-carboxylate；tert-butyl 4-[(3S)-4-benzyl-3-methylpiperazin-1-yl]-4-methylpiperidine-1-carboxylate
• CAS: 716339-53-6
• 化学式: C₂₃H₃₇N₃O₂
• 分子量: 387.566
• InChiKey: WNWJBYYOLYMCFJ-IBGZPJMESA-N

物化性质

• 沸点：
  472.2±45.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  36
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate 以100的产率得到Tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  Piperazinylpiperidine derivatives as chemokine receptor antagonists

  摘要：

  本发明涉及公式I的化合物：其中变量取代基在此定义，可调节或结合于趋化因子受体如CCR5的活性。在某些实施例中，本发明的化合物对CCR5具有选择性。这些化合物可用于治疗与趋化因子受体表达或活性相关的疾病，如炎症性疾病、免疫性疾病和病毒感染。

  公开号：

  US07678798B2
• 作为产物：
  描述：

  (S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-cyanopiperidine-1-carboxylate 以92.6的产率得到(S)-tert-butyl 4-(4-benzyl-3-methylpiperazin-1-yl)-4-methylpiperidine-1-carboxylate
  参考文献：
  名称：

  Piperazinylpiperidine derivatives as chemokine receptor antagonists

  摘要：

  本发明涉及公式I的化合物：其中变量取代基在此定义，可调节或结合于趋化因子受体如CCR5的活性。在某些实施例中，本发明的化合物对CCR5具有选择性。这些化合物可用于治疗与趋化因子受体表达或活性相关的疾病，如炎症性疾病、免疫性疾病和病毒感染。

  公开号：

  US07678798B2

文献信息

• Piperidine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US20040132711A1

  公开（公告）日：2004-07-08

  The present invention provides a compound of the formula 1 or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

  本发明提供了以下式的化合物1或其药学上可接受的盐或溶剂，其中各种基团如规范中所定义。本发明还提供了含有本发明化合物的药物组合物，以及使用本发明化合物的治疗方法。该发明还涉及使用本发明化合物与一种或多种抗病毒或其他对治疗人类免疫缺陷病毒（HIV）有用的药剂的组合。该发明进一步涉及使用本发明化合物，单独或与另一药剂结合，治疗固体器官移植排斥、移植物抗宿主病、关节炎、类风湿关节炎、炎症性肠病、特应性皮炎、牛皮癣、哮喘、过敏或多发性硬化症。
• Piperazine derivatives
  申请人：Liu Julie F.

  公开号：US20090270336A1

  公开（公告）日：2009-10-29

  This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc.

  该发明涉及一种新型化合物，即哌嗪衍生物，以及其药用盐。更具体地说，该发明涉及一种新型哌嗪化合物，即趋化因子CCR5受体拮抗剂维克利韦的衍生物。该发明还提供了不含致热原的组合物，包括该发明的一种或多种化合物和载体，以及使用所披露的化合物和组合物治疗通过给予趋化因子CCR5受体拮抗剂，如维克利韦，治疗的疾病和病况的方法。该发明还涉及使用所披露的一种或多种化合物作为试剂在涉及维克利韦的分析研究中。
• Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity
  作者：Chu-Biao Xue、Lihua Chen、Ganfeng Cao、Ke Zhang、Anlai Wang、David Meloni、Joseph Glenn、Rajan Anand、Michael Xia、Ling Kong、Taisheng Huang、Hao Feng、Changsheng Zheng、Mei Li、Laurine Galya、Jiacheng Zhou、Niu Shin、Fredric Baribaud、Kim Solomon、Peggy Scherle、Bitao Zhao、Sharon Diamond、Tom Emm、Douglas Keller、Nancy Contel、Swamy Yeleswaram、Kris Vaddi、Gregory Hollis、Robert Newton、Steven Friedman、Brian Metcalf

  DOI：10.1021/ml1001536

  日期：2010.12.9

  To identify a CCR5 antagonist as an HIV-1 entry inhibitor, we designed a novel series of indane derivatives based on conformational considerations. Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinity for CCR5, potent anti-HIV-1 activity, high receptor selectivity, excellent oral bioavailability, and a tolerated safety profile. INCB9471 has entered

  为了将CCR5拮抗剂鉴定为HIV-1进入抑制剂，我们基于构象考量设计了一系列新型的茚满衍生物。茚满环上的修饰导致发现化合物22a（INCB9471）对CCR5表现出高亲和力，有效的抗HIV-1活性，高受体选择性，出色的口服生物利用度和可耐受的安全性。INCB9471已进入人体临床试验。
• PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS
  申请人：Xue Chu-Biao

  公开号：US20120295912A1

  公开（公告）日：2012-11-22

  The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

  本发明涉及式I的化合物：其中变量取代基在此定义，可调节或结合于趋化因子受体如CCR5的活性。在某些实施例中，本发明的化合物对CCR5具有选择性。这些化合物可用于治疗与趋化因子受体表达或活性相关的疾病，如炎症性疾病、免疫性疾病和病毒感染。
• ACS Med. Chem. Lett. 2010, 1, 483-487
  作者：

  DOI：——

  日期：——